ATLASATLAS fair value
ATLAS has no fair value for this stock today.
Jw Life Science (234080.KO)
Jw Life Science stock price today, ATLAS forecast and fair value
Healthcare · Drug Manufacturers - Specialty & Generic · Korea Exchange (KOSPI) · South Korea
₩10,440▲ +0.19%
Prices as of Oct 27, 2026 · KRW
Chance of rising in 1 month
54%
that it ends higher than today in 21 sessions
0%coin flip 50%100%
This is just the summary. See everything on Jw Life Science in ATLAS
ATLAS's own quantitative analysis, all in one place.
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
See everything included
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
On Jw Life Science
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
And for you
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
Plans from €3.99 a month.
ATLAS's model gives Jw Life Science a 54% chance of finishing higher a month from now (21 trading sessions) than today: close to a coin flip.
In half of the simulated outcomes the price ends between ₩10,153 and ₩10,830; in 9 out of 10, between ₩9,589 and ₩11,467. Estimated annual volatility is 17%.
Price, last 12 months (weekly close)
Key numbers
- Market cap
- ₩160B
- Market cap (USD)
- $121M
- P/E ratio
- 6.3
- Dividend yield
- 5.20%
- 52-week high
- ₩15,580
- 52-week low
- ₩10,330
- Revenue (12 months)
- ₩254B
- Gross margin
- 28.2%
- Operating margin
- 14.8%
- Net margin
- 10.3%
- Beta
- 0.22
What this means
ATLAS does not publish a fair value for 234080.KO right now, but it does show its odds of rising: close to a coin flip.
Over the last 52 weeks 234080.KO has traded between ₩10,330 and ₩15,580. Today it is 33.0% below that high and 1% above its low.
On the business: net margin is 10.3%; it trades at 6.3 times earnings.
Its beta is 0.22: it tends to move less than the market.
About the company
JW Lifescience Corporation provides national infusion solutions in South Korea and internationally.
Want to see everything about Jw Life Science?
Get started →Plans from €3.99 a month.
Comparable companies
Other companies in the same line of business:
Frequently asked questions
What does Jw Life Science do?
JW Lifescience Corporation provides national infusion solutions in South Korea and internationally.
What is the chance 234080.KO goes up next month?
54%: close to a coin flip. In half of the simulated outcomes, 234080.KO ends the month between ₩10,153 and ₩10,830.
How big is Jw Life Science and what is its P/E ratio?
Jw Life Science's market capitalization is ₩160B. Its price-to-earnings (P/E) ratio is 6.3: you pay ₩6.30 for each ₩1.00 of yearly earnings.
Does Jw Life Science pay a dividend?
Yes. 234080.KO's current dividend yield is 5.20% at today's price (₩10,440).
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer